The FDA on March 18, 2019 approved TECENTRIQ® in combination with Carboplatin and Etoposide, for the first-line treatment of adult patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC). TECENTRIQ® is a product of Genentech Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
